secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001493152-24-023798
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte enters Phase 1b/2 trial of LB-100 + atezolizumab for metastatic colorectal cancer with NKI
--------------------------------------------------------------------------------

- Trial combines Lixte's PP2A inhibitor LB-100 with Roche's atezolizumab; company provides LB-100 only.
- Roche provides atezolizumab and financial support; Lixte has no obligation to reimburse trial costs.
- Phase 1b/2 study led by Dr. Neeltje Steeghs at NKI in Amsterdam; opens by June 30, 2024.
- Patient accrual up to 24 months; maximum 37 metastatic microsatellite stable colorectal cancer patients.
- Dose escalation to determine RP2D; expansion phase evaluates safety, tolerability, and pharmacokinetics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224023798/0001493152-24-023798-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224023798/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-023798

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer